Renal failure is present in 40% of heart failure patients, and is one of the main comorbidities of heart failure. Follow-up with pulmonary artery pressure (PAP) monitoring has shown a reduction in mortality and frequency of hospitalization in patients with heart failure alone in the CHAMPION trial. Patients with New York Heart Association class III heart failure and a hospitalization in the previous 12 months were included in that study. They benefited from the "CardioMEMS™ HF" device with a sensor implanted in the pulmonary artery to measure PAP. According to that study, the information led to more precise and early adaptation of therapy by avoiding the onset of heart failure symptoms and reducing the number of hospitalizations. However, in that study, patients with impaired renal function (Glomerular Filtration Rate\<25 mL/min/1.73m2) were excluded, limiting the indication for treatment in those patients, and the evolution of renal function during the study was not reported. Patients with heart failure AND advanced renal failure are defined as having a cardio-renal syndrome, with strong interaction between these 2 organs. In the event of predominant right heart failure, they may require treatment by renal replacement or dialysis. There seems to be a link between high venous pressure, renal repercussions and the need for dialysis. Additional follow-up data in this clinical situation are needed to confirm this link and to suggest the interest of continuous PAP monitoring to improve the management of these patients with cardio-renal syndrome with severe renal impairment defined by a Glomerular Filtration Rate\< 30 ml/min/1.73m2 (KDIGO Cardio-renal 2019). This pilot study aims to evaluate how tolerable the "CARDIOMEMS™ HF" device in patients with cardio-renal syndrome and obtain the first information on the relationship between cardiac hemodynamics and renal function in this population.
There are currently 1.5 million heart failure patients in France. The high morbidity and mortality make it a major public health issue. Renal failure, present in 40% of these patients, is one of the main comorbidities of heart failure and makes its management more complex. Medical follow-up with pulmonary artery pressure (PAP) monitoring has shown a reduction in mortality and frequency of hospitalization in patients with heart failure alone in the CHAMPION trial. Patients with New York Heart Association class III heart failure and a hospitalization in the previous 12 months were included in this study. They benefited from the "CardioMEMS™ HF" device with implantation of a sensor in the pulmonary artery allowing direct and continuous measurement of PAP. According to this study, this information allowed for more precise and early adaptation of therapy by avoiding the occurrence of heart failure symptoms and reducing the frequency of hospitalizations. In this study, patients with impaired renal function were excluded (Glomerular Filtration Rate \<25 mL/min/1.73m2), limiting the indication for treatment in these patients, and the evolution of renal function during the study was not reported. Patients with heart failure associated with advanced renal failure are defined as having a cardio-renal syndrome, with a strong interaction between these 2 organs that may, in particular in the case of predominant right heart failure, require treatment by renal replacement or dialysis. According to the data available to date, the predominant hypothesis is a link between high venous pressure, renal repercussions and the need for dialysis. Additional follow-up data in this clinical situation are needed to confirm this link and to suggest the interest of continuous monitoring of PAP to improve the management of these patients with cardio-renal syndrome with severe renal impairment defined by a Glomerular Filtration Rate\< 30 ml/min/1.73m2 (KDIGO Cardio-renal 2019). Therefore, the investigators wish to initiate a pilot study evaluating the tolerability of the "CARDIOMEMS™ HF" device in patients with cardio renal syndrome and obtain the first information on the relationship between cardiac hemodynamics and renal function in this population. This is the first pilot study on the safety and tolerability of the use of the CardioMEMS™ HF medical device in cardio renal syndrome with severe renal impairment (documented by Glomerular Filtration Rate \< 30 mL/min/1.73m2 measured by Iohexol clearance) treated medically and without renal replacement therapy. In this study, the CARDIOMEMS™ HF device, the most successful implanted pulmonary arterial pressure monitoring system currently available on the market will be implemented. Its teletransmitted information can guide the treatment of patients with heart failure.This system, by responding to the recent international recommendations which advocate a better understanding of the hemodynamic situation in this pathology with in particular the link between pulmonary arterial pressure and renal function, could help us to identify innovative evaluation tools with a view to improving therapeutic management with the new treatments available in heart failure (AA House et al: HF in kidney disease: a KDIGO conference report).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
10
The initial routine workup includes a nephrological evaluation: mGFR with Iohexol before fitting the CARDIOMEMS™ HF device, renal echo-Doppler, urinary sedimentation, etiological assessment of severe Chronic Kidney Disease, NT-ProBNP, impedancemetry, urinary ionogram, weight, anemia assessment, and correction of possible iron and/or vitamin deficiency and a cardiology evaluation: blood pressure, heart rate, clinical data, biology (Complete Blood Count, iono, urea, creatinine, total bilirubin, ferritin, CST), echocardiography (Left Ventricle Ejection Fraction, E/A, E/e', indexed volume of the left atrium, Tricuspid Annular Plane Systolic Excursion, Tissue Doppler S-wave, surface area of the right atrium, Systolic Pulmonary Artery Pressure, Right Atrial Pressure). The device will be implanted in the selected patients by Pr François Roubille at Montpellier University Hospital within 1 month of the pre-inclusion visit. It will monitor their pulmonary artery pressure.
Centre Hospitalier Universitaire de Nîmes
Nîmes, Gard, France
RECRUITINGCHRU de Montpellier - Hôpital Arnaud de Villeneuve
Montpellier, France
RECRUITINGAdverse events
Perioperative collection of complications related to the puncture site (hematoma, arteriovenous fistula) and right catheterization (arrhythmia, peri-procedure heart failure decompensation).
Time frame: On the day of implanting the Cardiomems device
Adverse events
Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement).
Time frame: One month after implanting the Cardiomems device
Adverse events
Perioperative collection of complications related to the puncture site (hematoma, arteriovenous fistula) and right catheterization (arrhythmia, peri-procedure heart failure decompensation). Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement).
Time frame: Two months after implanting the Cardiomems device
Adverse events
Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement).
Time frame: Three months after implanting the Cardiomems device
Adverse events
Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement).
Time frame: Four months after implanting the Cardiomems device
Adverse events
Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement).
Time frame: Five months after implanting the Cardiomems device
Adverse events
Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement).
Time frame: Six months after implanting the Cardiomems device
Adverse events
Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement).
Time frame: Seven months after implanting the Cardiomems device
Adverse events
Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement).
Time frame: Eight months after implanting the Cardiomems device
Adverse events
Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement).
Time frame: Nine months after implanting the Cardiomems device
Adverse events
Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement).
Time frame: Ten months after implanting the Cardiomems device
Adverse events
Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement).
Time frame: Eleven months after implanting the Cardiomems device
Adverse events
Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement).
Time frame: Twelve months after implanting the Cardiomems device
Estimated effect on renal function
The estimated Glomerular Filtration Rate (eGFR) will be recorded in mL/min
Time frame: Between 1 day to 1 month before implanting the device.
Measured effect on renal function
The Glomerular Filtration Rate measured with Iohexol (mGFR) will be recorded in mL/min.
Time frame: Between 1 day to 1 month before implanting the device.
Estimated effect on renal function
The estimated Glomerular Filtration Rate (eGFR) will be recorded in mL/min
Time frame: Day 0 (day of implanting the device)
Measured effect on renal function
The Glomerular Filtration Rate measured with Iohexol (mGFR) will be recorded in mL/min.
Time frame: Day 0 (day of implanting the device)
Estimated effect on renal function
The estimated Glomerular Filtration Rate (eGFR) will be recorded in mL/min
Time frame: Month 3
Measured effect on renal function
The Glomerular Filtration Rate measured with Iohexol (mGFR) will be recorded in mL/min.
Time frame: Month 3
Estimated effect on renal function
The estimated Glomerular Filtration Rate (eGFR) will be recorded in mL/min
Time frame: Month 6
Measured effect on renal function
The Glomerular Filtration Rate measured with Iohexol (mGFR) will be recorded in mL/min.
Time frame: Month 6
Estimated effect on renal function
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The estimated Glomerular Filtration Rate (eGFR) will be recorded in mL/min
Time frame: Month 9
Measured effect on renal function
The Glomerular Filtration Rate measured with Iohexol (mGFR) will be recorded in mL/min.
Time frame: Month 9
Estimated effect on renal function
The estimated Glomerular Filtration Rate (eGFR) will be recorded in mL/min.
Time frame: Month 12
Measured effect on renal function
The Glomerular Filtration Rate measured with Iohexol (mGFR) will be recorded in mL/min.
Time frame: Month 12
Re-hospitalizations
Any re-hospitalizations will be recorded for a period of up to 12 months of follow-up
Time frame: Month 12
Vital status
Patient dead or alive
Time frame: Month 12
Link between cardiac hemodynamics and renal function: Pulmonary Arterial Pressure
Pulmonary Arterial Pressure will be continuously monitored for 12 months by the CardioMEMS™ HF intracardiac device in patients with severe cardio-renal syndrome and measured in Hg.
Time frame: From Day 0 (day of implanting the device) to the end of Month 12
Link between cardiac hemodynamics and renal function: Glomerular Filtration Rate
Glomerular Filtration Rate will be measured by measuring plasma clearance of iohexol from a single sample.
Time frame: Day 0
Link between cardiac hemodynamics and renal function: Pulmonary Arterial Pressure
Pulmonary Arterial Pressure will be continuously monitored for 12 months by the CardioMEMS™ HF intracardiac device in patients with severe cardio-renal syndrome and measured in Hg. Readings will be recorded at 3-monthly intervals.
Time frame: Month 3
Link between cardiac hemodynamics and renal function: Glomerular Filtration Rate
Glomerular Filtration Rate will be measured in ml/min/1.72² by measuring plasma clearance of iohexol from a single sample.
Time frame: Month 3
Link between cardiac hemodynamics and renal function: Pulmonary Arterial Pressure
Pulmonary Arterial Pressure will be continuously monitored for 12 months by the CardioMEMS™ HF intracardiac device in patients with severe cardio-renal syndrome and measured in Hg. Readings will be recorded at 3-monthly intervals.
Time frame: Month 6
Link between cardiac hemodynamics and renal function: Glomerular Filtration Rate
Glomerular Filtration Rate will be measured in ml/min/1.72² by measuring plasma clearance of iohexol from a single sample.
Time frame: Month 6
Link between cardiac hemodynamics and renal function: Pulmonary Arterial Pressure
Pulmonary Arterial Pressure will be continuously monitored for 12 months by the CardioMEMS™ HF intracardiac device in patients with severe cardio-renal syndrome and measured in Hg. Readings will be recorded at 3-monthly intervals.
Time frame: Month 9
Link between cardiac hemodynamics and renal function: Glomerular Filtration Rate
Glomerular Filtration Rate will be measured in ml/min/1.72² by measuring plasma clearance of iohexol from a single sample.
Time frame: Month 9
Link between cardiac hemodynamics and renal function: Pulmonary Arterial Pressure
Pulmonary Arterial Pressure will be continuously monitored for 12 months by the CardioMEMS™ HF intracardiac device in patients with severe cardio-renal syndrome and measured in Hg. Readings will be recorded at 3-monthly intervals.
Time frame: Month 12
Link between cardiac hemodynamics and renal function: Glomerular Filtration Rate
Glomerular Filtration Rate will be measured in ml/min/1.72² by measuring plasma clearance of iohexol from a single sample.
Time frame: Month 12
Comparison of cardiac hemodynamic monitoring data with the clinical picture: exertional dyspnea
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. To quantify dyspnea, the patient is asked to indicate on a visual analog scale the point corresponding to his/her own perception, evaluated as the distance from the zero extreme (non dyspnea) and expressed as a percentage of the total length of the line.
Time frame: Day 0
Comparison of cardiac hemodynamic monitoring data with the clinical picture: exertional dyspnea
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. To quantify dyspnea, the patient is asked to indicate on a visual analog scale the point corresponding to his/her own perception, evaluated as the distance from the zero extreme (non dyspnea) and expressed as a percentage of the total length of the line.
Time frame: Month 3
Comparison of cardiac hemodynamic monitoring data with the clinical picture: exertional dyspnea
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. To quantify dyspnea, the patient is asked to indicate on a visual analog scale the point corresponding to his/her own perception, evaluated as the distance from the zero extreme (non dyspnea) and expressed as a percentage of the total length of the line.
Time frame: Month 6
Comparison of cardiac hemodynamic monitoring data with the clinical picture: exertional dyspnea
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. To quantify dyspnea, the patient is asked to indicate on a visual analog scale the point corresponding to his/her own perception, evaluated as the distance from the zero extreme (non dyspnea) and expressed as a percentage of the total length of the line.
Time frame: Month 9
Comparison of cardiac hemodynamic monitoring data with the clinical picture: exertional dyspnea
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. To quantify dyspnea, the patient is asked to indicate on a visual analog scale the point corresponding to his/her own perception, evaluated as the distance from the zero extreme (non dyspnea) and expressed as a percentage of the total length of the line.
Time frame: Month 12
Comparison of cardiac hemodynamic monitoring data with the clinical picture: NT-pro-BNP biomarkers
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Natriuretic Peptide Tests (BNP, NT-proBNP) will be made on a single blood sample. BNP and NT-proBNP will be measured as percentages.
Time frame: Day 0
Comparison of cardiac hemodynamic monitoring data with the clinical picture: NT-pro-BNP biomarkers
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Natriuretic Peptide Tests (BNP, NT-proBNP) will be made on a single blood sample. BNP and NT-proBNP will be measured in %.
Time frame: Month 3
Comparison of cardiac hemodynamic monitoring data with the clinical picture: NT-pro-BNP biomarkers
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Natriuretic Peptide Tests (BNP, NT-proBNP) will be made on a single blood sample. BNP and NT-proBNP will be measured as percentages.
Time frame: Month 6
Comparison of cardiac hemodynamic monitoring data with the clinical picture: NT-pro-BNP biomarkers
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Natriuretic Peptide Tests (BNP, NT-proBNP) will be made on a single blood sample. BNP and NT-proBNP will be measured as percentages.
Time frame: Month 9
Comparison of cardiac hemodynamic monitoring data with the clinical picture: NT-pro-BNP biomarkers
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Natriuretic Peptide Tests (BNP, NT-proBNP) will be made on a single blood sample. BNP and NT-proBNP will be measured as percentages.
Time frame: Month 12
Comparison of cardiac hemodynamic monitoring data with the clinical picture: left ventricular ejection fraction
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Left Ventricular Ejection Fraction will be measured as a percentage via the formula EF=SV/EDV (ejection fraction = stroke volume/end diastolic volume.
Time frame: Day 0
Comparison of cardiac hemodynamic monitoring data with the clinical picture: left ventricular ejection fraction
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Left Ventricular Ejection Fraction will be measured as a percentage via the formula EF=SV/EDV (ejection fraction = stroke volume/end diastolic volume.
Time frame: Month 3
Comparison of cardiac hemodynamic monitoring data with the clinical picture: left ventricular ejection fraction
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Left Ventricular Ejection Fraction will be measured as a percentage via the formula EF=SV/EDV (ejection fraction = stroke volume/end diastolic volume.
Time frame: Month 6
Comparison of cardiac hemodynamic monitoring data with the clinical picture: left ventricular ejection fraction
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Left Ventricular Ejection Fraction will be measured as a percentage via the formula EF=SV/EDV (ejection fraction = stroke volume/end diastolic volume.
Time frame: Month 9
Comparison of cardiac hemodynamic monitoring data with the clinical picture: left ventricular ejection fraction
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Left Ventricular Ejection Fraction will be measured as a percentage via the formula EF=SV/EDV (ejection fraction = stroke volume/end diastolic volume.
Time frame: Month 12
Comparison of cardiac hemodynamic monitoring data with the clinical picture: E/A
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. E/A will be measured as a ratio.
Time frame: Month 0
Comparison of cardiac hemodynamic monitoring data with the clinical picture: E/A
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. E/A will be measured as a ratio (the E/A ratio is the ratio of the early (E) to late (A) ventricular filling velocities).
Time frame: Month 3
Comparison of cardiac hemodynamic monitoring data with the clinical picture: E/A
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. E/A will be measured as a ratio (the E/A ratio is the ratio of the early (E) to late (A) ventricular filling velocities).
Time frame: Month 6
Comparison of cardiac hemodynamic monitoring data with the clinical picture: E/A
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. E/A will be measured as a ratio (the E/A ratio is the ratio of the early (E) to late (A) ventricular filling velocities).
Time frame: Month 9
Comparison of cardiac hemodynamic monitoring data with the clinical picture: E/A
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. E/A will be measured as a ratio (the E/A ratio is the ratio of the early (E) to late (A) ventricular filling velocities).
Time frame: Month 12
Comparison of cardiac hemodynamic monitoring data with the clinical picture: E/e'
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. E/e' will be measured as a ratio.
Time frame: Month 0
Comparison of cardiac hemodynamic monitoring data with the clinical picture: E/e'
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. E/e' will be measured as a ratio (E= early diastolic transmitral flow velocity and e' = early diastolic mitral annular velocity).
Time frame: Month 3
Comparison of cardiac hemodynamic monitoring data with the clinical picture: E/e'
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. E/e' will be measured as a ratio (E= early diastolic transmitral flow velocity and e' = early diastolic mitral annular velocity).
Time frame: Month 6
Comparison of cardiac hemodynamic monitoring data with the clinical picture: E/e'
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. E/e' will be measured as a ratio (E= early diastolic transmitral flow velocity and e' = early diastolic mitral annular velocity).
Time frame: Month 9
Comparison of cardiac hemodynamic monitoring data with the clinical picture: E/e'
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. E/e' will be measured as a ratio (E= early diastolic transmitral flow velocity and e' = early diastolic mitral annular velocity).
Time frame: Month 12
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Indexed left atrial volume
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Indexed left atrial volume will be measured in ml/m2.
Time frame: Month 0
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Indexed left atrial volume
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Indexed left atrial volume will be measured in ml/m2.
Time frame: Month 3
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Indexed left atrial volume
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Indexed left atrial volume will be measured in ml/m2.
Time frame: Month 6
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Indexed left atrial volume
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Indexed left atrial volume will be measured in ml/m2.
Time frame: Month 9
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Indexed left atrial volume
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Indexed left atrial volume will be measured in ml/m2.
Time frame: Month 12
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Tricuspid Annular Plane Systolic Excursion
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Tricuspid Annular Plane Systolic Excursion will be measured in cm.
Time frame: Month 0
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Tricuspid Annular Plane Systolic Excursion
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Tricuspid Annular Plane Systolic Excursion will be measured in cm.
Time frame: Month 3
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Tricuspid Annular Plane Systolic Excursion
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Tricuspid Annular Plane Systolic Excursion will be measured in cm.
Time frame: Month 6
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Tricuspid Annular Plane Systolic Excursion
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Tricuspid Annular Plane Systolic Excursion will be measured in cm.
Time frame: Month 9
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Tricuspid Annular Plane Systolic Excursion
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Tricuspid Annular Plane Systolic Excursion will be measured in cm.
Time frame: Month 12
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Tissue Doppler S-wave
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Tissue Doppler S-wave will be measured in mV
Time frame: Month 0
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Tissue Doppler S-wave
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Tissue Doppler S-wave will be measured in mV
Time frame: Month 3
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Tissue Doppler S-wave
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Tissue Doppler S-wave will be measured in mV
Time frame: Month 6
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Tissue Doppler S-wave
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Tissue Doppler S-wave will be measured in mV
Time frame: Month 9
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Tissue Doppler S-wave
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Tissue Doppler S-wave will be measured in mV
Time frame: Month 12
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Right atrium area
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Right atrium area will be measured in cm2.
Time frame: Month 0
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Right atrium area
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Right atrium area will be measured in cm2.
Time frame: Month 3
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Right atrium area
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Right atrium area will be measured in cm2.
Time frame: Month 6
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Right atrium area
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Right atrium area will be measured in cm2.
Time frame: Month 9
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Right atrium area
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Right atrium area will be measured in cm2.
Time frame: Month 12
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Systolic pulmonary artery pressure
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Systolic pulmonary artery pressure will be measured in mmHg.
Time frame: Month 0
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Systolic pulmonary artery pressure
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Systolic pulmonary artery pressure will be measured in mmHg.
Time frame: Month 3
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Systolic pulmonary artery pressure
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Systolic pulmonary artery pressure will be measured in mmHg.
Time frame: Month 6
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Systolic pulmonary artery pressure
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Systolic pulmonary artery pressure will be measured in mmHg.
Time frame: Month 9
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Systolic pulmonary artery pressure
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Systolic pulmonary artery pressure will be measured in mmHg.
Time frame: Month 12
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Right atrial pressure
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Right atrial pressure will be measured in mmHg.
Time frame: Month 0
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Right atrial pressure
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Right atrial pressure will be measured in mmHg.
Time frame: Month 3
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Right atrial pressure
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Right atrial pressure will be measured in mmHg.
Time frame: Month 6
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Right atrial pressure
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Right atrial pressure will be measured in mmHg.
Time frame: Month 9
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Right atrial pressure
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Right atrial pressure will be measured in mmHg.
Time frame: Month 12
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Stroke volume
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Stroke volume (SV) will be measured and recorded in millilitres per square metre (ml/m2).
Time frame: Day 0
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Stroke volume
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Stroke volume (SV) will be measured and recorded in millilitres per square metre (ml/m2).
Time frame: Month 3
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Stroke volume
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Stroke volume (SV) will be measured and recorded in millilitres per square metre (ml/m2).
Time frame: Month 6
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Stroke volume
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Stroke volume (SV) will be measured and recorded in millilitres per square metre (ml/m2).
Time frame: Month 9
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Stroke volume
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Stroke volume (SV) will be measured and recorded in millilitres per square metre (ml/m2).
Time frame: Month 12
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Heart rate
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. The patient's heart rate (HR) will be measured and recorded as beats per minute (BPM).
Time frame: Day 0
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Heart rate
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. The patient's heart rate (HR) will be measured and recorded as beats per minute (BPM).
Time frame: Month 3
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Heart rate
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. The patient's heart rate (HR) will be measured and recorded as beats per minute (BPM).
Time frame: Month 6
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Heart rate
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. The patient's heart rate (HR) will be measured and recorded as beats per minute (BPM).
Time frame: Month 9
Comparison of cardiac hemodynamic monitoring data with the clinical picture: Heart rate
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. The patient's heart rate (HR) will be measured and recorded as beats per minute (BPM).
Time frame: Month 12
Comparison of cardiac hemodynamic monitoring data with the clinical picture: cardiac output
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Cardiac output (CO) will be measured and recorded in liters per minute.
Time frame: Day 0
Comparison of cardiac hemodynamic monitoring data with the clinical picture: cardiac output
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Cardiac output (CO) will be measured and recorded in liters per minute.
Time frame: Month 3
Comparison of cardiac hemodynamic monitoring data with the clinical picture: cardiac output
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Cardiac output (CO) will be measured and recorded in liters per minute.
Time frame: Month 6
Comparison of cardiac hemodynamic monitoring data with the clinical picture: cardiac output
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Cardiac output (CO) will be measured and recorded in liters per minute.
Time frame: Month 9
Comparison of cardiac hemodynamic monitoring data with the clinical picture: cardiac output
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Cardiac output (CO) will be measured and recorded in liters per minute.
Time frame: Month 12
Comparison of cardiac hemodynamic monitoring data with the clinical picture: ventricular ejection time
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Ventricular ejection time (VET) will be measured and recorded in milliseconds.
Time frame: Day 0
Comparison of cardiac hemodynamic monitoring data with the clinical picture: ventricular ejection time
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Ventricular ejection time (VET) will be measured and recorded in milliseconds.
Time frame: Month 3
Comparison of cardiac hemodynamic monitoring data with the clinical picture: ventricular ejection time
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Ventricular ejection time (VET) will be measured and recorded in milliseconds.
Time frame: Month 6
Comparison of cardiac hemodynamic monitoring data with the clinical picture: ventricular ejection time
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Ventricular ejection time (VET) will be measured and recorded in milliseconds.
Time frame: Month 9
Comparison of cardiac hemodynamic monitoring data with the clinical picture: ventricular ejection time
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Ventricular ejection time (VET) will be measured and recorded in milliseconds.
Time frame: Month 12
Comparison of cardiac hemodynamic monitoring data with the clinical picture: pre-ejection period
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Stroke volume (SV), heart rate (HR), cardiac output (CO) ventricular ejection time (VET) and pre-ejection period (PER) will all be measured and recorded in milliseconds.
Time frame: Day 0
Comparison of cardiac hemodynamic monitoring data with the clinical picture: pre-ejection period
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Stroke volume (SV), heart rate (HR), cardiac output (CO) ventricular ejection time (VET) and pre-ejection period (PER) will all be measured and recorded in milliseconds.
Time frame: Month 3
Comparison of cardiac hemodynamic monitoring data with the clinical picture: pre-ejection period
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Stroke volume (SV), heart rate (HR), cardiac output (CO) ventricular ejection time (VET) and pre-ejection period (PER) will all be measured and recorded in milliseconds.
Time frame: Month 6
Comparison of cardiac hemodynamic monitoring data with the clinical picture: pre-ejection period
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Stroke volume (SV), heart rate (HR), cardiac output (CO) ventricular ejection time (VET) and pre-ejection period (PER) will all be measured and recorded in milliseconds .
Time frame: Month 9
Comparison of cardiac hemodynamic monitoring data with the clinical picture: pre-ejection period
The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Stroke volume (SV), heart rate (HR), cardiac output (CO) ventricular ejection time (VET) and pre-ejection period (PER) will all be measured and recorded in milliseconds.
Time frame: Month 12
Patient quality of life
The patient's quality of life will be evaluated using the EQ-5D questionnaire. This questionnaire essentially consists of two pages: the EQ-5D descriptive system (page 2 of the questionnaire) and the EQ-5D visual analog scale (EQ VAS) (page 3 of the questionnaire) ranging from 0 - 100 in which 0 = extremely bad health and 100 = excellent health. EQ-5D is not an abbreviation and is the correct term to use when referring to the instrument. The EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression.
Time frame: Day 0
Patient quality of life
The patient's quality of life will be evaluated using the EQ-5D questionnaire. This questionnaire essentially consists of two pages: the EQ-5D descriptive system (page 2 of the questionnaire) and the EQ-5D visual analog scale (EQ VAS) (page 3 of the questionnaire) ranging from 0 - 100 in which 0 = extremely bad health and 100 = excellent health. EQ-5D is not an abbreviation and is the correct term to use when referring to the instrument. The EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression.
Time frame: Month 3
Patient quality of life
The patient's quality of life will be evaluated using the EQ-5D questionnaire. This questionnaire essentially consists of two pages: the EQ-5D descriptive system (page 2 of the questionnaire) and the EQ-5D visual analog scale (EQ VAS) (page 3 of the questionnaire) ranging from 0 - 100 in which 0 = extremely bad health and 100 = excellent health. EQ-5D is not an abbreviation and is the correct term to use when referring to the instrument. The EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression.
Time frame: Month 6
Patient quality of life
The patient's quality of life will be evaluated using the EQ-5D questionnaire. This questionnaire essentially consists of two pages: the EQ-5D descriptive system (page 2 of the questionnaire) and the EQ-5D visual analog scale (EQ VAS) (page 3 of the questionnaire) ranging from 0 - 100 in which 0 = extremely bad health and 100 = excellent health. EQ-5D is not an abbreviation and is the correct term to use when referring to the instrument. The EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression.
Time frame: Month 9
Patient quality of life
The patient's quality of life will be evaluated using the EQ-5D questionnaire. This questionnaire essentially consists of two pages: the EQ-5D descriptive system (page 2 of the questionnaire) and the EQ-5D visual analog scale (EQ VAS) (page 3 of the questionnaire). EQ-5D is not an abbreviation and is the correct term to use when referring to the instrument. The EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The EQ -5D is scored from 0 -100 and the VAS is scored from 0 -10.
Time frame: Month 12